全文获取类型
收费全文 | 246548篇 |
免费 | 21523篇 |
国内免费 | 8955篇 |
专业分类
耳鼻咽喉 | 1825篇 |
儿科学 | 3521篇 |
妇产科学 | 2876篇 |
基础医学 | 37667篇 |
口腔科学 | 3925篇 |
临床医学 | 19133篇 |
内科学 | 47475篇 |
皮肤病学 | 3486篇 |
神经病学 | 17719篇 |
特种医学 | 5283篇 |
外国民族医学 | 55篇 |
外科学 | 17733篇 |
综合类 | 31655篇 |
现状与发展 | 25篇 |
一般理论 | 48篇 |
预防医学 | 13581篇 |
眼科学 | 2941篇 |
药学 | 37937篇 |
61篇 | |
中国医学 | 9967篇 |
肿瘤学 | 20113篇 |
出版年
2023年 | 5385篇 |
2022年 | 7030篇 |
2021年 | 13956篇 |
2020年 | 11686篇 |
2019年 | 8231篇 |
2018年 | 7936篇 |
2017年 | 7755篇 |
2016年 | 7907篇 |
2015年 | 9163篇 |
2014年 | 14298篇 |
2013年 | 16139篇 |
2012年 | 13883篇 |
2011年 | 16042篇 |
2010年 | 13039篇 |
2009年 | 13276篇 |
2008年 | 12937篇 |
2007年 | 12142篇 |
2006年 | 10875篇 |
2005年 | 9483篇 |
2004年 | 8060篇 |
2003年 | 7229篇 |
2002年 | 5745篇 |
2001年 | 4803篇 |
2000年 | 4040篇 |
1999年 | 3514篇 |
1998年 | 2912篇 |
1997年 | 2853篇 |
1996年 | 2457篇 |
1995年 | 2517篇 |
1994年 | 2243篇 |
1993年 | 1899篇 |
1992年 | 1602篇 |
1991年 | 1462篇 |
1990年 | 1194篇 |
1989年 | 1004篇 |
1988年 | 941篇 |
1987年 | 784篇 |
1986年 | 712篇 |
1985年 | 1389篇 |
1984年 | 1442篇 |
1983年 | 1063篇 |
1982年 | 1048篇 |
1981年 | 910篇 |
1980年 | 779篇 |
1979年 | 659篇 |
1978年 | 502篇 |
1977年 | 396篇 |
1976年 | 428篇 |
1975年 | 375篇 |
1973年 | 265篇 |
排序方式: 共有10000条查询结果,搜索用时 46 毫秒
41.
Major depressive disorder and other neuropsychiatric disorders are often managed with long-term use of antidepressant medication. Fluoxetine, an SSRI antidepressant, is widely used as a first-line treatment for neuropsychiatric disorders. However, fluoxetine has also been shown to increase the risk of metabolic diseases such as non-alcoholic fatty liver disease. Fluoxetine has been shown to increase hepatic lipid accumulation in vivo and in vitro. In addition, fluoxetine has been shown to alter the production of prostaglandins which have also been implicated in the development of non-alcoholic fatty liver disease. The goal of this study was to assess the effect of fluoxetine exposure on the prostaglandin biosynthetic pathway and lipid accumulation in a hepatic cell line (H4-II-E-C3 cells). Fluoxetine treatment increased mRNA expression of prostaglandin biosynthetic enzymes (Ptgs1, Ptgs2, and Ptgds), PPAR gamma (Pparg), and PPAR gamma downstream targets involved in fatty acid uptake (Cd36, Fatp2, and Fatp5) as well as production of 15-deoxy-Δ12,14PGJ2 a PPAR gamma ligand. The effects of fluoxetine to induce lipid accumulation were attenuated with a PTGS1 specific inhibitor (SC-560), whereas inhibition of PTGS2 had no effect. Moreover, SC-560 attenuated 15-deoxy-Δ12,14PGJ2 production and expression of PPAR gamma downstream target genes. Taken together these results suggest that fluoxetine-induced lipid abnormalities appear to be mediated via PTGS1 and its downstream product 15d-PGJ2 and suggest a novel therapeutic target to prevent some of the adverse effects of fluoxetine treatment. 相似文献
42.
《Vaccine》2022,40(13):1924-1927
High vaccine reactogenicities may reflect stronger immune responses, but the epidemiological evidence for coronavirus disease 2019 (COVID-19) vaccines is sparse and inconsistent. We observed that a fever of ≥38℃ after two doses of the BNT162b2 vaccine was associated with higher severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike IgG titers. 相似文献
43.
Immunogenicity of heterologous inactivated and adenoviral-vectored COVID-19 vaccine: Real-world data
《Vaccine》2022,40(23):3203-3209
Limited data are available on the responses to heterologous vaccine regimens for SARS-CoV-2, especially among countries using inactivated and adenoviral-vectored vaccines. A total of 77 participants who received heterologous inactivated COVID-19 vaccine (CoronaVac) and adenoviral-vectored vaccine (AZD1222) were enrolled in our study. There were two comparison groups vaccinated with the homologous CoronaVac (N = 79) and AZD1222 (N = 78) regimen. All sera samples were tested for anti-receptor-binding-domain IgG (anti-RBD IgG) using a chemiluminescent microparticle immunoassay (CMIA). The neutralizing activity in a subset of serum samples was tested against the original Wuhan strain and variants of concern, B.1.1.7, B.1.617.2 and B.1.351, using an enzyme-linked immunosorbent assay (ELISA)-based surrogate virus neutralization test (sVNT). The heterologous CoronaVac/AZD1222 vaccine induced higher levels of anti-RBD IgG than that of two-dose homologous CoronaVac or AZD1222 vaccines (p < 0.001). Sera samples of the CoronaVac/AZD1222 vaccine recipients elicited higher neutralizing antibody activity against the original Wuhan and all variants of concern than in the recipients of the two-dose CoronaVac. The heterologous CoronaVac followed by AZD1222 is an alternative regimen to combat with the SARS-CoV-2 variants in case of vaccine shortage with improved immunogenicity compared to the homologous CoronaVac regimen. 相似文献
44.
《Vaccine》2022,40(32):4296-4300
Advanced computational methodologies suggested SARS-CoV-2, nonstructural proteins ORF1AB, ORF3a, as the source of immunodominant peptides for T cell presentation. T cell immunity is long-lasting and compatible with COVID-19 pathology. Based on the supporting clinical data, nonstructural SARS-CoV-2 protein vaccines could provide global immunity against COVID-19. 相似文献
45.
《Vaccine》2022,40(44):6431-6444
This is a Brighton Collaboration case definition of thrombosis and thromboembolism to be used in the evaluation of adverse events following immunization, and for epidemiologic studies for the assessment of background incidence or hypothesis testing. The case definition was developed by a group of experts convened by the Coalition for Epidemic Preparedness Innovations (CEPI) in the context of active development of SARS-CoV-2 vaccines. The case definition format of the Brighton Collaboration was followed to develop a consensus definition and defined levels of certainty, after an exhaustive review of the literature and expert consultation. The document underwent peer review by the Brighton Collaboration Network and by selected expert reviewers prior to submission. 相似文献
46.
《Clinical microbiology and infection》2022,28(8):1152.e1-1152.e6
ObjectivesDespite the possibility of concurrent infection with COVID-19 and malaria, little is known about the clinical course of coinfected patients. We analysed the clinical outcomes of patients with concurrent COVID-19 and malaria infection.MethodsWe conducted a retrospective cohort study that assessed prospectively collected data of all patients who were admitted between May and December 2020 to the Universal COVID-19 treatment center (UCTC), Khartoum, Sudan. UCTC compiled demographic, clinical, laboratory (including testing for malaria), and outcome data in all patients with confirmed COVID-19 hospitalized at that clinic. The primary outcome was all-cause mortality during the hospital stay. We built proportional hazard Cox models with malaria status as the main exposure and stepwise adjustment for age, sex, cardiovascular comorbidities, diabetes, and hypertension.ResultsWe included 591 patients with confirmed COVID-19 diagnosis who were also tested for malaria. Mean (SD) age was 58 (16.2) years, 446/591 (75.5%) were males. Malaria was diagnosed in 270/591 (45.7%) patients. Most malaria patients were infected by Plasmodium falciparum (140/270; 51.9%), while 121/270 (44.8%) were coinfected with Plasmodium falciparum and Plasmodium vivax. Median follow-up was 29 days. Crude mortality rates were 10.71 and 5.87 per 1000 person-days for patients with and without concurrent malaria, respectively. In the fully adjusted Cox model, patients with concurrent malaria and COVID-19 had a greater mortality risk (hazard ratio 1.43, 95% confidence interval 1.21-1.69).DiscussionCoinfection with COVID-19 and malaria is associated with increased all-cause in-hospital mortality compared to monoinfection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). 相似文献
47.
We present the case of a male patient with severe SARS-CoV-2 pneumonia, with simultaneous onset of p-ANCA positive rapidly progressive glomerulonephritis. We discuss the different therapeutic possibilities, emphasising the appropriateness of their administration according to the time in the course of the infection. 相似文献
48.
49.
50.